Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Medical Oncology (Northwood, London, England)|August 16, 2002
Simultaneous presentation of hepatocellular carcinoma in identical twin brothersGokhan Demir, Sedef Belentepe, Mustafa Ozguroglu, et al.
Onkologie|August 8, 2012
Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe painKadri Altundag, Omer Dizdar, Zeynep Ozsaran, et al.
Medical Oncology (Northwood, London, England)|August 4, 2007
Paraneoplastic pemphigus associated with fludarabine useOzcan Yildiz, Mustafa Ozguroglu, M Teoman Yanmaz, et al.
Clinical Genitourinary Cancer|December 15, 2016
Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter StudyMarie Auvray, Reza Elaidi, Mustafa Ozguroglu, et al.
Lancet (London, England)|October 5, 2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialJohann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trialRodryg Ramlau, Vera Gorbunova, Tudor Eliade Ciuleanu, et al.
Hepato-Gastroenterology|April 28, 2015
Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?Mehmet Akif Ozturk, Faysal Dane, Sila Karagoz, et al.
The Oncologist|June 27, 2025
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer ConsortiumElif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, et al.
The Lancet. Oncology|April 19, 2014
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialFabrice André, Ruth O'Regan, Mustafa Ozguroglu, et al.
Clinical Lung Cancer|February 28, 2019
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study ProtocolBenjamin Levy, Luis Paz-Ares, Jaafar Bennouna, et al.
Pageof 4